Targeted Therapies for Immunological Non-Responders in People With HIV: A Multicenter Clinical Study

Exclusion Criteria

• •1. Co-infection with other viruses: positive for any of HBV, HCV, HDV, or HEV; or CMV/EBV viral load \> 1000 copies/mL.
• •2. HIV-2 infection alone or co-infection with HIV-1 and HIV-2.
• •3. History of using efavirenz or rilpivirine within 2 years prior to enrollment.
• •4. History of NNRTI resistance.
• •5. Clinical signs suggestive of other serious diseases.
• •6. Long-term use of corticosteroids or other immunosuppressive agents.
• •7. Co-existing severe AIDS-related or non-AIDS-related events.
• •8. Co-existing severe underlying diseases of other systems not related to AIDS.
• •9. Other severe organic diseases or psychiatric disorders, including any uncontrolled clinically significant disease of the urinary, circulatory, respiratory, nervous, psychiatric, digestive, endocrine, immune systems, or malignancy.
• •10. Receipt of immunosuppressive or systemic cytotoxic therapy within 6 months prior to screening.
• •11. Evidence of substance abuse within 6 months prior to enrollment, or a positive urine drug screen.
• •12. Current participation in another clinical trial that may conflict with the treatment protocol or outcome measures of this study.
• •13. Pregnancy, breastfeeding, or women who have a desire to become pregnant.
• •14. Inability or unwillingness to provide informed consent or comply with study requirements.
• •15. Any other serious condition that may interfere with the conduct of the clinical trial.